In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment

Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

(2010) Gabor G. Illei et al.   ARTHRITIS AND RHEUMATISM

Current aspects of anti-CD20 therapy in rheumatoid arthritis

(2010) Annett M Jacobi et al.   CURRENT OPINION IN PHARMACOLOGY

Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation

(2010) Shigeru Kotake et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Alterations on peripheral blood B-cell subpopulations in very early arthritis patients

(2010) R. A. Moura et al.   RHEUMATOLOGY

Rapid and sustained improvement in bone and cartilage turnover markers with the anti–interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone

(2009) Patrick Garnero et al.   ARTHRITIS AND RHEUMATISM

Interleukin-6 as a key player in systemic inflammation and joint destruction

(2009) J.E. Fonseca et al.   AUTOIMMUNITY REVIEWS

IL-6 produced by immune complex-activated follicular dendritic cells promotes germinal center reactions, IgG responses and somatic hypermutation

(2009) Yongzhong Wu et al.   INTERNATIONAL IMMUNOLOGY

The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+T cells

(2009) Oliver Dienz et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor

(2009) Jean-Michel Dayer et al.   RHEUMATOLOGY

Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor

(2009) M Margarida Souto-Carneiro et al.   ARTHRITIS RESEARCH & THERAPY

Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis

(2009) Maria J Leandro   ARTHRITIS RESEARCH & THERAPY

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

(2008) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Anti-CD20 therapy in patients with rheumatoid arthritis: Predictors of response and B cell subset regeneration after repeated treatment

(2008) Petra Roll et al.   ARTHRITIS AND RHEUMATISM

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

(2008) N. Nishimoto et al.   BLOOD

Role of the spleen in peripheral memory B-cell homeostasis in patients with autoimmune thrombocytopenia purpura

(2008) Lorena Martinez-Gamboa et al.   CLINICAL IMMUNOLOGY

Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B-cell roadblock hypothesis

(2008) Gregg J. Silverman et al.   IMMUNOLOGICAL REVIEWS